SATO VICKI L 4
4 · Allogene Therapeutics, Inc. · Filed Jun 23, 2026
Research Summary
AI-generated summary of this filing
Allogene (ALLO) Director Vicki L. Sato Receives RSU Award
What Happened
- Vicki L. Sato, a director of Allogene Therapeutics, was granted 95,400 restricted stock units (RSUs) on 2026-06-18. The Form 4 reports the award as an acquisition (code A) at $0.00 (non‑cash equity award). Each RSU represents a contingent right to one share of common stock.
Key Details
- Transaction date: 2026-06-18; Form 4 filed: 2026-06-23.
- Award: 95,400 RSUs; reported price on Form 4: $0.00 (award/derivative).
- Vesting: RSUs vest in two equal semi‑annual installments over one year from the grant date (see footnote).
- Shares owned after transaction: not specified in the filing.
- Filing timeliness: Form 4 was filed on 2026-06-23 for a 2026-06-18 grant (SEC Form 4s are typically due within two business days; this filing appears one business day past that window).
Context
- RSUs are a promise to deliver shares in the future subject to vesting and continued service; they are not an immediate cash purchase or sale. Grants to directors are a common form of compensation and do not, by themselves, indicate a buy or sell decision in the market.
Insider Transaction Report
Form 4
SATO VICKI L
Director
Transactions
- Award
Restricted Stock Unit
[F1]2026-06-18+95,400→ 95,400 total→ Common Stock (95,400 underlying)
Footnotes (1)
- [F1]Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.
Signature
/s/Earl Douglas, Attorney-in-Fact|2026-06-23